- Raised $5M funding round led by NGT3, Jul 2020
- Raised $2.5M grant, Jul 2023
- Raised funding round, Aug 2022
About
ELGAN Pharma is a clinical-stage neonatology-focused biotechnology company developing safe, tailored therapies to address medical problems and developmental difficulties common in babies born very early.
The company has two leading clinical programs: ELGN-GI and ELGN-EYE. Both therapies address high unmet medical needs of preterm infants with no existing solutions to date.
ELGN-GI promotes a faster maturation of an infant’s intestines, allowing them to rapidly reach full enteral feeding and become independent from parenteral nutrition while minimizing serious complications and reducing burden and costs to healthcare systems. The product has completed several clinical trials, including a successful phase 3, and is currently starting a second phase 2.
ELGN-EYE is a local drug targeted at preventing vision impairment due to retinopathy of prematurity (ROP), a condition caused by the underdeveloped blood vessels in the eyes of premature babies at the time of birth. ROP is the leading cause of blindness in children worldwide. A phase 1 study of the product was successfully concluded and a phase 2 is currently launching.
Funding history · 3 rounds · $7.5M total
Q&A
- What is ELGAN Pharma's primary focus?
- ELGAN Pharma is a clinical-stage neonatology-focused biotechnology company developing tailored therapies for medical problems and developmental difficulties in premature babies.
- What are ELGAN Pharma's two main clinical programs?
- ELGAN Pharma has two leading clinical programs: ELGN-GI, which promotes faster maturation of an infant’s intestines, and ELGN-EYE, a local drug aimed at preventing vision impairment due to retinopathy of prematurity (ROP).
- What is the current development stage of ELGN-GI?
- The ELGN-GI product has completed several clinical trials, including a successful Phase 3, and is currently starting a second Phase 2 study.
- What is the current development stage of ELGN-EYE?
- A Phase 1 study of ELGN-EYE was successfully concluded, and a Phase 2 study is currently launching.
- When was ELGAN Pharma founded?
- ELGAN Pharma was founded in May 2018.
- What was ELGAN Pharma's most recent funding event?
- In July 2023, ELGAN Pharma received a Grant of $2,500,000 from EIC Accelerator.
- Who are the co-founders of ELGAN Pharma?
- The co-founders of ELGAN Pharma are Miki Olshansky (CEO) and Stav Zeldis (VP Regulatory Affairs).
- How many employees does ELGAN Pharma have?
- ELGAN Pharma has 11-50 employees.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | elganpharma.com |
|---|---|
| linkedin.com/company/67923556 |
Identifiers & details
| Founded | 2018-5 |
|---|---|
| Employees (exact) | 25 |
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | elganpharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|